Newsfeeds - Spark Newswire

5 minute read

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer’s Conference, IPOs and More

Today, 12:46 PM

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.

ABBV

1 minute read

Cathie Wood’s ARK Invest Posts Fund Purchases For Thursday, July 15, 2021: RPTX, VERV, FATE, SGFY, QSI, COIN, EXAS, U, KTOS, MKFG, PATH, CND, KVSB

By Michael Horton

Today, 12:46 PM

Repare Therapeutics (RPTX) - 39,887 Shares Verve Therapeutics (VERV) - 60,256 Fate Therapeutics (FATE) - 152,712 Signify Health (SGFY) - 36,732 Quantum-Si (QSI) - 347,305 Coinbase Global (COIN) - 69,172 Exact

CND

1 minute read

Cathie Wood’s ARK Invest Posts Fund Purchases For Wednesday, July 14, 2021: FTCH, VERV, EXAS, FATE, SGFY, RPTX, PATH, QSI, COIN, U, KTOS, MELI, KVSB, CND

By Michael Horton

Today, 12:46 PM

Farfetch (FTCH) - 77,832 Shares Verve Therapeutics (VERV) - 80,425 Exact Sciences (EXAS) - 82,938 Fate Therapeutics (FATE) - 70,126 Signify Health (SGFY) - 99,674 Repare Therapeutics (RPTX) - 201,765 UiPath

CND

1 minute read

10 Biggest Price Target Changes For Monday

By Lisa Levin

Today, 12:46 PM

SVB Leerink raised Natera, Inc. (NASDAQ: NTRA) price target from $140 to $160. Natera shares fell 0.4% to close at $102.88 on Friday.

AAT

1 minute read

Wells Fargo Maintains Equal-Weight on Exact Sciences, Raises Price Target to $120

By Benzinga Newsdesk

Today, 12:46 PM

Wells Fargo analyst Dan Leonard maintains Exact Sciences (NASDAQ:EXAS) with a Equal-Weight and raises the price target from $115 to $120.

EXAS

16 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For June 15, 2021

By Benzinga Insights

Today, 12:46 PM

ACRS

1 minute read

Raymond James Initiates Coverage On Exact Sciences with Strong Buy Rating, Announces Price Target of $160

By Benzinga Newsdesk

Today, 12:46 PM

Raymond James analyst Andrew Cooper initiates coverage on Exact Sciences (NASDAQ:EXAS) with a Strong Buy rating and announces Price Target of $160.

EXAS

10 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For June 3, 2021

By Benzinga Insights

Today, 12:46 PM

ADC

1 minute read

Goldman Sachs Initiates Coverage On Exact Sciences with Buy Rating, Announces Price Target of $160

By Benzinga Newsdesk

Today, 12:46 PM

Goldman Sachs analyst Matthew Sykes initiates coverage on Exact Sciences (NASDAQ:EXAS) with a Buy rating and announces Price Target of $160.

EXAS

1 minute read

Uncategorized

Why Exact Sciences Is Trading Higher Today

By Adam Eckert

Today, 12:46 PM

Exact Sciences Corp (NASDAQ: EXAS) is trading higher Thursday after the company announced it will showcase new data on its cancer tests and treatment guidance tools in an upcoming presentation.

EXAS